Randomized trial · people
Eloralintide: -4.4% body weight at week 4 in a single-dose trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In healthy people, one dose of eloralintide was mostly well tolerated and lowered weight over 4 weeks, but this single-dose trial does not show what repeated dosing does in people with obesity.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 48
- Published
- 2025
- Journal
- Mol Metab
What they tested
The team tested how eloralintide acts on amylin-related receptors in cells, what it does to eating and weight in rats, and whether single doses are safe and tolerated in healthy people.
How the study was done
Lab tests in cell lines carrying rat or human amylin or calcitonin receptors, studies in rats and monkeys, and a phase 1 randomized, placebo-controlled, blinded trial of single rising doses (0.04-12 mg) in 48 healthy participants. In the trial, neither participants nor investigators knew who got the drug or placebo (a dummy treatment).

Model. Individual results vary.
What they found
In cell lines, eloralintide favored the human AMY1R receptor, activating it 12-fold more than CTR and 11-fold more than AMY3R. In rats, it caused less conditioned taste avoidance (a learned dislike of a taste) than cagrilintide (p < 0.05), and in diet-induced obese rats it lowered food intake and body weight in a dose-dependent way, mostly through fat loss. In the human trial, participants on eloralintide reported 16 adverse events, and 15 of the 16 were mild; there were 4 gastrointestinal events, including one moderate vomiting event. At week 4, body weight changed by -2.5% in the 4 mg arm (p < 0.01) and -4.4% in the 12 mg arm (p < 0.001), vs +0.6% on placebo.
What it doesn’t show
The human part was a small phase 1 safety trial of single doses in healthy people, with weight checked at week 4, so it does not show long-term weight loss or safety in people with obesity. The receptor, taste avoidance and fat loss results come from cells and rats, not people.
The paper
Briere et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025.
The compound
More studies on Eloralintide
- Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1Randomized trial · people · 2026
- Every study on Eloralintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.